FDA Kicks Off Opioid Class REMS Discussion; Asks For Industry Collaboration
Executive Summary
FDA laid out general guidelines for a class-wide Risk Evaluation and Mitigation Strategy for opioid pain products during a closed-door meeting March 3, and urged manufacturers to work collaboratively to help develop a proposal as soon as possible
You may also be interested in...
As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class
In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.
REMS For Opioids: Industry Considering Prescriber, Dispenser Certification
Drug makers have agreed on communications, education components of strategy.
Opioid Class REMS: FDA Wants Prescriber/Pharmacist Certification
Public meeting set for end of May: next step on the difficult road to a class-wide REMS. Important precedent in the making.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: